Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.97 |
| ▸ | HTR2A | P28223 | 7/20 | 0.97 |
| ▸ | HTR1A | P08908 | 7/20 | 0.97 |
| ▸ | HTR1D | P28221 | 6/20 | 0.97 |
| ▸ | HTR1B | P28222 | 4/20 | 0.97 |
| ▸ | HTR7 | P34969 | 3/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | HTR5A | P47898 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.97 |
| ▸ | HTR3B | O95264 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | HTR1E | P28566 | 1/20 | 0.97 |
| ▸ | HTR1F | P30939 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serotonin SCHEMBL1495 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL29349412 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL30057954 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL183226 | 0.98 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL25341783 | 0.97 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL8208967 | 0.97 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL29781387 | 0.97 | HTR2C (1.00) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL28576451 | 0.97 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL3091827 | 0.97 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| Serotonin SCHEMBL1675866 | 0.97 | HTR2C (0.97) | HTR2CHTR2AHTR1AHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269141-A1 | TARGET PROTEIN AND TARGET GENE FOR DRUG DISCOVERY, AND SCREENING METHOD | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-11-03 | — | — | US | claimed |
| US-20060281752-A1 | Method for the normalization of sexual response and amelioration of long term genital tissue degradation | HEATON JEREMY P W | 2006-12-14 | — | — | US | claimed |
| CN-1269484-C | Serotonergic 5HT2 agonists for treating glaucoma | ALCON LAB INC (US) | 2006-08-16 | — | — | CN | claimed |
| EP-1666040-A1 | Methods for the normalization of sexual response and amelioration of long term genital tissue regradation | TAP Pharmaceutical Products, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| US-20030092725-A1 | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation | HEATON JEREMY P W (CA) | 2003-05-15 | — | — | US | claimed |
| US-20020193442-A1 | Method and compositions for the treatment or amelioration of female sexual dysfunction | Parteq Innovations (CA) | 2002-12-19 | — | — | US | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| US-20020165122-A1 | Method and compositions for the treatment or amelioration of female sexual dysfunction | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-11-07 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| CN-1317979-A | 5-hydroxytryptamine-activating agonists for the treatment of glaucoma | ALCON LAB INC (US) | 2001-10-17 | — | — | CN | claimed |
| EP-1089736-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-04-11 | — | — | EP | claimed |
| WO-1999066909-A2 | METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION | UNIV KINGSTON (CA) | 1999-12-29 | — | — | WO | claimed |
| US-20250114406-A1 | METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM BLOOD PRODUCTS | SANA BIOTECHNOLOGY, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2024098098-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural MedTech Pty Ltd (AU) | 2024-05-16 | — | — | WO | disclosed |
| US-11903975-B2 | Methods and compositions relating to chondrisomes from blood products | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11903974-B2 | Methods and compositions relating to chondrisomes from cultured cells | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| WO-1996029074-A1 | METHODS OF TREATING OR PREVENTING PAIN OR NOCICEPTION | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996024353-A1 | METHODS OF TREATING OR PREVENTING PSYCHIATRIC DISORDERS | ELI LILLY AND COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0710479-A1 | Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine | ELI LILLY AND COMPANY (US) | 1996-05-08 | — | — | EP | disclosed |
| WO-1996011000-A1 | METHODS OF TREATING MIGRAINE | ELI LILLY AND COMPANY (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092725-A1 | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation | KISS1R, OXTR, GNRHR | HTR2C 685/4885HTR2A 228/4885HTR1A 222/4885 |
| US-20020165122-A1 | Method and compositions for the treatment or amelioration of female sexual dysfunction | OXTR, GNRHR, VIPR2 | HTR2C 357/4885HTR2A 1112/4885HTR1A 870/4885 |
| US-20060281752-A1 | Method for the normalization of sexual response and amelioration of long term genital tissue degradation | OXTR, KISS1R, GNRHR | HTR2C 695/4885HTR2A 230/4885HTR1A 234/4885 |
| US-20020193442-A1 | Method and compositions for the treatment or amelioration of female sexual dysfunction | GNRHR, LHCGR, FSHR | HTR2C 264/4885HTR2A 1050/4885HTR1A 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.